|
Federal Working Group on Dietary Supplements (FWGoDS)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, CDC, FDA, HRSA, IHS, OS
|
OD/DPCPSI/ODP, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ORWH
|
The Office of Dietary Supplements (ODS) leads the Federal Working Group on Dietary Supplements (FWGoDS) which is comprised of individuals from federal agencies that share information and discuss issues, initiatives, and research related to dietary supplements. The FWGoDS facilitates communication and collaboration between NIH and its federal partners in several ways: co-funding research investigations within the NIH, expanding opportunities for research-investigator training, and strengthening collaborative efforts involving dietary supplement research, education, and communication. The FWGoDS meets twice a year and serves as a means of communication between ODS and its federal partners.
|
|
FedTel: Cross-Federal work group on telehealth
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIBIB, NLM, OD/DPCPSI/OBSSR
|
The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. Current topics of emphasis include Telehealth and Health Information Technology (HIT); Technology, Innovation and Standards; Public Education of Telehealth; and Access to Health Care.
|
|
Filovirus Animal Non-Clinical Group (FANG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories.
|
|
FNIH Biomarkers Consortium
|
Research Initiative
|
CMS, FDA
|
NIMH, NCATS, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NINDS
|
The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.
|
|
FNIH PACT (Partnership for Accelerating Cancer Therapies)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $215 million launched by the National Institutes of Health, the FNIH (Foundation for the NIH) and 11 leading pharmaceutical companies as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the FNIH, with the Food and Drug Administration serving in an advisory role.
|
|
Fogarty HIV Research Training Program and AIDS International Training and Research Program (AITRP)
|
Training Initiative
|
CDC
|
FIC, NIDA
|
The goal of the Fogarty HIV Research Training Program (AITRP) is to build multi-disciplinary bio-medical, behavioral, and social science research capacity for the prevention, care, and treatment of HIV/AIDS and HIV-related conditions in adults and children in low- and middle- income countries (LMIC). Research training will be provided to scientists at institutions in countries defined by the World Bank criteria as LMIC. In FY15, PEPFAR/CDCCOP funded one supplement to a parent AITRP award in Ukraine through SUNY Medical Center Downstate. Also, research training activities in Uganda continued to be supported in FY15 through the FY14 PEPFAR/CDC-COP funded supplement to the Fogarty HIV Research Training award at the University of California, Berkeley.
|
|
Forum on Regenerative Medicine
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDCR, NHLBI, NIAMS, NIBIB, NIDDK, NINDS
|
Six NIH institutes and FDA are participating in a multi-year National Academy of Medicine (NAM)-led activity entitled "Forum on Regenerative Medicine". The objective of the Forum is to engage key stakeholders of regenerative medicine in a dialogue about opportunities and challenges facing translation of regenerative medicine science and technologies to the clinic. The setting of the NAM provides a neutral convening mechanism for interactions between academia, industry, government, regulators, patients’ organizations, foundations, and others. In addition to science, ethical, legal, and societal issues related to regenerative
medicine are discussed. In October 2016 the Forum supported a highly successful interdisciplinary workshop that examined the current state of science in regenerative medicine. Further activities are currently being planned.
|
|
Full-text health-related documents at NLM (includes HSTAT)
|
Resource Development
|
AHRQ, ATSDR, CDC, CMS, FDA, OSG, SAMHSA
|
NLM
|
The National Library of Medicine of the National Institutes of Health provides a free, web-based resource of full-text documents that provide information on health-care decision making.
|
|
Funding Opportunity Announcement Module (FOAM)
|
Resource Development
|
ACF
|
OD/OER, NHLBI
|
The Funding Opportunity Announcement Module (FOAM) allows NIH Institutes and Centers and HHS Operating Divisions to develop content for and perform the needed approvals to publish funding opportunity announcements. The system has a flexible configuration to meet all of the needs for HHS Operating Divisions. Furthermore, FOAM achieves economies of scale by preventing the need for individual agencies to develop duplicate systems at a cost much greater than that of developing a unified system.
|
|
Gabriella Miller Kids First Common Fund Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, NCATS, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAID, NIAMS, NIDA, NIDCR, NIDDK, NIEHS, NINDS, OD/DPCPSI/ORIP, OD/DPCPSI/OSC, OD/ECHO
|
The NIH Gabriella Miller Kids First Common Fund Working Group supports the goals and initiatives of the NIH Gabriella Miller First Common Fund Pediatric Research Program. The Common Fund’s Gabriella Miller Kids First Pediatric Research program (Kids First) is developing a data resource for the pediatric research community of well-curated clinical and genetic sequence data that will allow scientists to identify genetic pathways that underlie specific pediatric conditions but that may also be shared between apparently disparate conditions. A representative from CDC participates in the Kids First Working Group.
|